Report
EUR 13.98 For Business Accounts Only

APHRIA sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of APHRIA (CA), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 2 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date January 26, 2021, the closing price was CAD 16.45 and its target price was estimated at CAD 6.50.
Underlying
Aphria Inc

Aphria is engaged in the production, supply and sale of medical cannabis in Canada. Co.'s medical cannabis is 100% greenhouse grown and comes in a range of products such as capsules, oral solutions, syringes and vaporizers. Co.'s cannabis capsules contain a precise dose of active cannabinoids in the form of purified cannabis oil. Co.'s oral solution contains purified cannabis oil in a liquid form. Co.'s syringe products are versatile and can be consumed in various forms, including orally or heated at a high temperature. Co.'s single-unit vaporizer cartridges are pre-filled with purified cannabis oil made from cannabis plant extract and natural terpenes.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch